221 related articles for article (PubMed ID: 36001101)
1. Health care utilization and costs associated with functional status in patients with psoriatic arthritis.
Ogdie A; Hwang M; Veeranki P; Portelli A; Sison S; Shafrin J; Pedro S; Hass S; Hur P; Kim N; Yi E; Michaud K
J Manag Care Spec Pharm; 2022 Sep; 28(9):997-1007. PubMed ID: 36001101
[No Abstract] [Full Text] [Related]
2. Association of health care utilization and costs with patient-reported outcomes in patients with ankylosing spondylitis.
Ogdie A; Hwang M; Veeranki P; Portelli A; Sison S; Shafrin J; Pedro S; Kim N; Yi E; Michaud K
J Manag Care Spec Pharm; 2022 Sep; 28(9):1008-1020. PubMed ID: 36001102
[No Abstract] [Full Text] [Related]
3. Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit.
Fendrick AM; Brixner D; Rubin DT; Mease P; Liu H; Davis M; Mittal M
J Manag Care Spec Pharm; 2021 Aug; 27(8):1086-1095. PubMed ID: 33843252
[No Abstract] [Full Text] [Related]
4. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
Brixner D; Rubin DT; Mease P; Mittal M; Liu H; Davis M; Ganguli A; Fendrick AM
J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.
Murage MJ; Princic N; Park J; Malatestinic WN; Zhu B; Atiya B; Kern SA; Stenger KB; Sprabery AT; Ogdie A
J Manag Care Spec Pharm; 2022 Feb; 28(2):206-217. PubMed ID: 35098751
[No Abstract] [Full Text] [Related]
6. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
[No Abstract] [Full Text] [Related]
7. Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States.
Sanchez L; Chari A; Cheng M; Cherepanov D; DerSarkissian M; Huang F; Stull DM; Dabora J; Young M; Noga SJ; Pi S; Zhang M; Banatwala A; Duh MS; Ailawadhi S
J Manag Care Spec Pharm; 2023 Nov; 29(11):1205-1218. PubMed ID: 37776124
[No Abstract] [Full Text] [Related]
8. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
Smith MR; Sandhu S; George DJ; Chi KN; Saad F; Thiery-Vuillemin A; Stàhl O; Olmos D; Danila DC; Gafanov R; Castro E; Moon H; Joshua AM; Mason GE; Espina BM; Liu Y; Lopez-Gitlitz A; Francis P; Bevans KB; Fizazi K
J Manag Care Spec Pharm; 2023 Jul; 29(7):758-768. PubMed ID: 37404070
[No Abstract] [Full Text] [Related]
9. Annual costs among patients with major depressive disorder and the impact of key clinical events.
Cutler AJ; Keyloun KR; Higa S; Park J; Bonafede M; Gillard P; Jain R
J Manag Care Spec Pharm; 2022 Dec; 28(12):1335-1343. PubMed ID: 36427344
[No Abstract] [Full Text] [Related]
10. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
[TBL] [Abstract][Full Text] [Related]
11. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
[TBL] [Abstract][Full Text] [Related]
12. CME/CNE Article: A Framework of Care in Multiple Sclerosis, Part 1: Updated Disease Classification and Disease-Modifying Therapy Use in Specific Circumstances.
Newsome SD; Aliotta PJ; Bainbridge J; Bennett SE; Cutter G; Fenton K; Lublin F; Northrop D; Rintell D; Walker BD; Weigel M; Zackowski K; Jones DE
Int J MS Care; 2016; 18(6):314-323. PubMed ID: 27999526
[TBL] [Abstract][Full Text] [Related]
13. The Economic Burden of ACPA-Positive Status Among Patients with Rheumatoid Arthritis.
Shafrin J; Tebeka MG; Price K; Patel C; Michaud K
J Manag Care Spec Pharm; 2018 Jan; 24(1):4-11. PubMed ID: 29290168
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States.
Tepper SJ; Fang J; Zhou L; Shen Y; Vo P; Abdrabboh A; Glassberg MB; Ferraris M
J Manag Care Spec Pharm; 2021 Sep; 27(9):1157-1170. PubMed ID: 33998825
[No Abstract] [Full Text] [Related]
15. Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis.
Strand V; Tundia N; Song Y; Macaulay D; Fuldeore M
J Manag Care Spec Pharm; 2018 Apr; 24(4):344-352. PubMed ID: 29578852
[TBL] [Abstract][Full Text] [Related]
16. For which diseases do broader value elements matter most? An evaluation across 20 ICER evidence reports.
Shafrin J; Dennen S; Pednekar P; Birch K; Bhor M; Kanter J; Neumann P
J Manag Care Spec Pharm; 2021 May; 27(5):650-659. PubMed ID: 33779245
[No Abstract] [Full Text] [Related]
17. Economic Impact of Above-Label Dosing with Etanercept, Adalimumab, or Ustekinumab in Patients with Psoriasis.
Feldman SR; Zhao Y; Zhou H; Herrera V; Tian H; Li Y
J Manag Care Spec Pharm; 2017 May; 23(5):583-589. PubMed ID: 28448778
[TBL] [Abstract][Full Text] [Related]
18. Health Care Resource Utilization and Costs in First-Line Treatments for Patients with Metastatic Melanoma in the United States.
Klink AJ; Chmielowski B; Feinberg B; Ahsan S; Nero D; Liu FX
J Manag Care Spec Pharm; 2019 Aug; 25(8):869-877. PubMed ID: 30945965
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Economic Burden of Psoriatic Arthritis and the Relationship Between Functional Status and Healthcare Costs.
McHugh N; Maguire Á; Handel I; Tillett W; Morris J; Hawkins N; Cavill C; Korendowych E; Mughal F
J Rheumatol; 2020 May; 47(5):701-707. PubMed ID: 31416922
[TBL] [Abstract][Full Text] [Related]
20. Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data.
Sundaram M; Song Y; Rogerio JW; Zhang S; Bhattacharya R; Adejoro O; Carley C; Zhu JJ; Signorovitch J; Haas NB
J Manag Care Spec Pharm; 2022 Oct; 28(10):1149-1160. PubMed ID: 36048895
[No Abstract] [Full Text] [Related]
[Next] [New Search]